Asian Market’s May 2026 Stocks Priced Below Estimated Value

As the Asian markets navigate a complex landscape shaped by geopolitical developments and economic fluctuations, investors are increasingly focused on identifying stocks that may be undervalued relative to their potential. In this environment, a good stock is often characterized by strong fundamentals and resilience to external pressures, offering opportunities for those seeking value in an ever-evolving market.

Top 10 Undervalued Stocks Based On Cash Flows In Asia

Click here to see the full list of 184 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

We’ll examine a selection from our screener results.

Innovent Biologics

Overview: Innovent Biologics, Inc. is a biopharmaceutical company focused on the research and development of antibody and protein medicine products across China, the United States, Europe, and other international markets with a market cap of HK$144.88 billion.

Operations: The company’s revenue primarily comes from its biotechnology segment, generating CN¥13.04 billion.

Estimated Discount To Fair Value: 41.2%

Innovent Biologics is trading at HK$83.35, significantly below its estimated future cash flow value of HK$141.82, suggesting it may be undervalued based on cash flows. Despite recent insider selling, Innovent’s profitability and revenue growth outpace the Hong Kong market. The strategic alliance with Pfizer could enhance long-term cash flows through a US$650 million upfront payment and potential milestone payments up to US$10.5 billion, bolstering its financial position amidst strong earnings growth forecasts.

• Insights from our recent growth report point to a promising forecast for Innovent Biologics’ business outlook.

• Dive into the specifics of Innovent Biologics here with our thorough financial health report.

Akeso

Overview: Akeso, Inc. is a biopharmaceutical company focused on the research, development, manufacture, and commercialization of antibody drugs globally, with a market cap of approximately HK$108.79 billion.

Operations: The company’s revenue segment primarily consists of CN¥3.06 billion from the research, development, production, and sale of biopharmaceutical products.